<!doctype data-preserve-html-node="true" html>

Untitled Document



3:00 – 3:30 p.m.

Registration & Networking

3:30 – 3:50 p.m.

Welcome & Introduction


William C. Geary III
Partner, Intellectual Property
Nutter McClennen & Fish

3:50 – 4:15 p.m.

Keynote Speaker


Robert S. Langer, Sc.D.
David H. Koch Institute Professor
Massachusetts Institute of Technology

4:15 – 5:15 p.m.

Panel I: Trends in Early-Stage Finance and Deal Structures




Laurie Halloran
Chief Executive Officer
Halloran Consulting Group




Omar Amirana, M.D.
Managing Director
Allied Minds


Alexis Borisy
Third Rock Ventures


Bill McPhee
Angel Investor
Managing Director, Praxis Advisors


Susan R. Windham-Bannister, Ph.D.
President and CEO
Massachusetts Life Sciences Center


The amount of venture capital invested in the life sciences sector during the second quarter of 2012 decreased for the fourth consecutive quarter, shrinking by 39% compared to the same period in 2011. In spite of the adverse funding environment, and perhaps because of it, experimentation with innovative early-stage funding models and deal structures is taking place among development-stage life science companies, venture capital funds, and large pharmaceutical and medical device firms.
Our panel of life science venture capitalists and angel investors will explore recent funding collaborations between venture capital and large life science companies, innovative ways to attract investment and generate shareholder returns, the role of non-dilutive capital, and other mechanisms to preserve value for founders and early investors of emerging life sciences companies.

5:15 – 5:30 p.m.


5:30 – 6:30 p.m.

Panel II: Building Blocks of Successful Business Development–Maximizing Value Creation and Attracting Buyers




Michelle L. Basil
Partner, Life Sciences Group
Nutter McClennen & Fish




David H. Donabedian, Ph.D.
Senior Vice President
Locust Walk Partners


Paul LaViolette
SV Life Sciences


Leslie J. Williams, B.S., R.N., M.B.A.
Chief Executive Officer


Leading a successful life sciences company requires the formulation and execution of a multi-dimensional business development plan. This panel will discuss the key building-blocks for a successful business development strategy that positions a life science company for an attractive exit opportunity. Topics examined will include the importance of clinical strategy, planning for regulatory and reimbursement challenges, negotiating strategic collaborations, and how and when to engage with potential acquirers or partners.

6:30 – 7:30 p.m.

Cocktails & Hors d’oeuvres